Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
Public ClinicalTrials.gov record NCT00789828. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.
Study identification
- NCT ID
- NCT00789828
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 117 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2009 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Oct 2014 (Actual)
- Last update posted
- Feb 3, 2016
2009 – 2014
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Barrow Tuberous Sclerosis Center | Phoenix | Arizona | 85013 | — |
| University of California at Los Angeles | Los Angeles | California | 90048 | — |
| Children's Hospital Oakland Hematology/Oncology Dept | Oakland | California | 94609-1809 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30342 | — |
| University of CHicago Comer Children's Hospital | Chicago | Illinois | 60637-1470 | — |
| Massachusetts General Hospital Mass General | Boston | Massachusetts | 02114 | — |
| Children's Hospital Boston SC-1 | Boston | Massachusetts | 02115 | — |
| Minnesota Epilepsy Group - PA | Saint Paul | Minnesota | 55102-2383 | — |
| Cincinnati Children's Hospital Medical Center Cincinnati Children's Hosp | Cincinnati | Ohio | 45229-3039 | — |
| Texas Scottish Rite Hospital for Children | Dallas | Texas | 75219 | — |
| Children's Regional Outpatients Center SC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00789828, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2016 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00789828 live on ClinicalTrials.gov.